H.C. Wainwright analyst Mitchell Kapoor downgraded Instil Bio (TIL) to Neutral from Buy without a price target saying AXN-2510’s discontinuation eliminates the stock’s core value driver. Investors should step to the sidelines as management evaluates strategic alternatives, with capital allocation now the key determinant of Instil’s residual value, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TIL:
- Instil Bio Ends Key Oncology Licensing Agreement with ImmuneOnco
- Baird downgrades Instil Bio on discontinuation of AXN-2510
- Instil Bio downgraded to Neutral from Outperform at Baird
- Instil Bio’s Axion discontinues clinical development of AXN-2510
- Instil Bio reports Q3 EPS ($1.75) vs ($2.55) last year